# Retatrutide vs CagriSema, Mazdutide & More: 2026 Data Source: https://www.philippinespeptides.com/guides/retatrutide-vs-next-generation Updated: 2026-10-01 > Retatrutide, cagrilintide, CagriSema, survodutide, mazdutide and amycretin compared: mechanism, best published figure, trial and approval stage in 2026. On this page - [Snapshot](#snapshot) - [The Comparison Table](#the-table) - [Limits of Cross-Trial Reading](#limits) - [Mechanism Map](#mechanism) - [The Amylin Route](#amylin) - [The Glucagon Duals](#glucagon-duals) - [Amycretin and the Oral Question](#amycretin) - [Where Retatrutide Sits](#where-reta) - [Filing Timelines and PH Context](#timelines) - [FAQ](#faq) - [Sources](#sources) - [Related guides](#related) Guides · Pipeline # Retatrutide vs the Next Generation Philippines Peptides editorial desk Updated 1 October 2026 18 min read Short answer Retatrutide holds the largest published phase 3 weight-reduction figure among the next-generation obesity compounds, 28.3% at 80 weeks in TRIUMPH-1, but trails on regulation: mazdutide was approved in China in June 2025 and CagriSema was filed in the US in December 2025, while retatrutide's US filing is planned for Q1 2027. **Compounds covered** - 6 **Approved anywhere** - 1 **Filed, under review** - 1 **Head to head trials** - 0 Related - [Retatrutide vs tirzepatide](https://www.philippinespeptides.com/guides/retatrutide-vs-tirzepatide) - [Retatrutide vs semaglutide](https://www.philippinespeptides.com/guides/retatrutide-vs-semaglutide) - [Cagrilintide](https://www.philippinespeptides.com/peptides/cagrilintide) - [Mazdutide](https://www.philippinespeptides.com/peptides/mazdutide) Video guide: Retatrutide vs Tirzepatide vs Semaglutide (2:18) Retatrutide, tirzepatide or semaglutide? Three generations of GLP-1 research, compared for the Philippines. Semaglutide acts on one receptor, GLP-1. Tirzepatide adds GIP. Retatrutide adds glucagon: three. Phase 3, top arm: semaglutide, 14.9% in STEP 1. Tirzepatide, 20.9 in SURMOUNT-1. Retatrutide, 28.3 in TRIUMPH-1. Separate trials, different people, no head-to-head yet. TRIUMPH-5, retatrutide against tirzepatide, has not read out. Stopping for side effects, top arm: 5.9% on semaglutide, 6.2 on tirzepatide, 11.3 on retatrutide. Nausea led: 53.3% on semaglutide, 42.4 on retatrutide, and TRIUMPH-1 reported dysesthesia in 12.5. Here, semaglutide is registered as Ozempic and Wegovy, tirzepatide as Mounjaro, both prescription only. Retatrutide is registered nowhere. Prescribing belongs with a licensed Philippine physician. Next: Lilly plans retatrutide's US filing for early 2027, CagriSema is under FDA review, and mazdutide is approved in China. All three also come as research vials: not the same product, not approved for human use, and sold for research only. Our partner and supplier, Primara Labs, lists all three as 15 mg vials. Retatrutide: [₱3,390 for the 20 mg vial], or [₱2,076] in a 10 pack. About ₱199 per mg, or ₱122 in a 10 pack. A 20 mg vial is now listed at ₱3,390. Every order includes bacteriostatic water, syringes and alcohol pads, ships same day in Metro Manila before noon, and has a 60-day money-back guarantee. Read the full comparison on Philippines Peptides, then see retatrutide at Primara Labs and order on WhatsApp. [Figures in square brackets corrected on 3 November 2026 from Primara's current catalogue: the narration gives the price of the 15 mg retatrutide vial, retired on 12 October 2026.] Part of: [Retatrutide in the Philippines](https://www.philippinespeptides.com/guides/retatrutide-philippines-2026) ## Snapshot **LARGEST PH3 FIGURERetatrutide, 80 wk** - 28.3% **FIRST APPROVEDChina, Jun 2025** - Mazdutide **FIRST FILED, USDec 2025** - CagriSema **RETA FILINGPlanned BLA** - Q1 2027 The shape of the field in two sentences. Retatrutide holds the largest published Phase 3 weight reduction figure of anything on this page, by a clear margin, and it is **behind two of its competitors on regulatory progress**, one of which is already approved in a major market while retatrutide has not yet been filed anywhere. Efficacy leadership and market leadership are separate races. Most comparison pages report only the first. Our partner and supplier Research vials: cost per mg | Product | Price | Per mg | | --- | --- | --- | | Primara Labs Retatrutide 20mg research vial20 mg per vial | ₱3,390₱2,076 each in a 10-pack | ₱170₱104 in a 10-pack | | Primara Labs Tirzepatide 15mg research vial15 mg per vial | ₱1,890₱1,155 each in a 10-pack | ₱126₱77 in a 10-pack | | Primara Labs Semaglutide 15mg research vial15 mg per vial | ₱1,990₱1,216 each in a 10-pack | ₱133₱81 in a 10-pack | Research vials are not approved for human use, are sold for research only, and must be reconstituted. - Stocked in Metro Manila; same-day delivery there for orders before 12 noon - Lab report: Janoshik, batch RETA-4728-A, retatrutide, bacterial endotoxin only; not identity or purity. Key [H2KI86I8GWB4](https://verify.janoshik.com/tests/234146_H2KI86I8GWB4), [batch reports](https://www.primaralabs.com/coa?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=bridge&utm_content=retatrutide-vs-next-generation) - [60-day money-back guarantee](https://www.primaralabs.com/guarantee?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=bridge&utm_content=retatrutide-vs-next-generation) - GCash, Maya, QR Ph bank transfer, InstaPay Primara Labs is our partner and supplier. ## The Comparison Table Best published weight reduction figure for each compound, with the trial that produced it and the duration over which it was measured. Figures are from sponsor releases or peer-reviewed publications, not from trackers or secondary reporting. Obesity pipeline, next generation compounds, as at August 2026 | Compound | Mechanism | Best published figure | Trial and duration | Stage | Filing | | --- | --- | --- | --- | --- | --- | | Retatrutide | GIP + GLP-1 + glucagon triple agonist | 28.3% | TRIUMPH-1, 80 weeks, n=2,339. 30.3% at 104 weeks in a 532-participant extension. | Phase 3, four readouts complete | BLA to FDA planned Q1 2027 | | Cagrilintide | Long-acting amylin analogue | 10.8% | Phase 2 dose-finding, 26 weeks, 4.5mg, against 3.0% placebo and 9.0% liraglutide. | Advanced as part of CagriSema | Not filed as monotherapy | | CagriSema | Cagrilintide plus semaglutide, one weekly injection | 22.7% | REDEFINE-1, 68 weeks, n=3,417, trial product estimand. 20.4% under treatment policy. | Phase 3 complete, under FDA review | NDA filed 18 Dec 2025, review expected 2026 | | Survodutide | Glucagon + GLP-1 dual agonist | 16.6% | SYNCHRONIZE-1, 76 weeks, n=725, efficacy estimand, against 3.2% placebo. | Phase 3, first readout May 2026 | No date disclosed | | Mazdutide | Glucagon + GLP-1 dual agonist | 18.6% | GLORY-2, 60 weeks, n=462 with obesity, 9mg, against 3.0% placebo. 20.1% in the subgroup without type 2 diabetes. | Approved in China at 4mg and 6mg | NMPA approval Jun 2025; 9mg NDA to China CDE | | Amycretin | Unimolecular GLP-1 + amylin receptor agonist | 24.3% | Phase 1b/2a, 36 weeks, subcutaneous 60mg, n=125, against 1.1% placebo. Preliminary. | Advancing to Phase 3 | No date disclosed | For orientation against the approved generation: tirzepatide reported 22.5% over 72 weeks in SURMOUNT-1 and semaglutide 14.9% over 68 weeks in STEP 1. Those durations differ from every row above, which is the point of the next section. Caution ### Which figures are preliminary **Amycretin at 24.3% is the weakest evidence on the table.** It comes from a phase 1b/2a study of 125 participants, not a pivotal trial. Early-phase figures in this field have repeatedly moved when tested at scale, and this one should be read as promising rather than established. **Cagrilintide at 10.8% is a dose-finding result** from a phase 2 trial, and monotherapy is not the development path the compound is on. **Survodutide has one Phase 3 readout, not a programme.** Further trial results were expected during 2026, and the full SYNCHRONIZE-1 dataset was scheduled for presentation at the American Diabetes Association Scientific Sessions in June 2026. ## What a Cross-Trial Table Cannot Tell You Every row above comes from a different trial. There is no head to head study between any two compounds on this page, which means the table is an assembly of separate experiments and not a competition. Four specific things break the comparison. **Duration.** The durations here run from 26 weeks to 80, plus a 104-week extension. Weight reduction curves in this class rise steeply and then flatten, so a longer trial reports a larger number partly because it ran longer. Comparing 28.3% at 80 weeks against 16.6% at 76 weeks is closer to fair than comparing it against 10.8% at 26 weeks, and neither is clean. **Estimand.** This is the most underappreciated source of difference, and REDEFINE-1 demonstrates it inside a single trial: 22.7% under the trial product estimand, which models the outcome if everyone stayed on treatment, and 20.4% under the treatment policy estimand, which counts everyone regardless. Same participants, 2.3 percentage points apart. SYNCHRONIZE-1 reported 16.6% under an efficacy estimand. Reading one convention against another silently imports that gap. **Population.** The rows are not describing the same people. GLORY-2 enrolled Chinese adults with a BMI of 30 or above, and Chinese obesity trial populations typically start at lower absolute body weights than western ones, which affects percentage outcomes. TRIUMPH-1 enrolled a general obesity population, TRIUMPH-2 people with type 2 diabetes, TRIUMPH-3 people with established cardiovascular disease. Baseline BMI, diabetes status and background care all move the result. **Trial scale and phase.** A number from 2,339 randomised participants and a number from 125 are not the same kind of claim. The confidence interval around an early-phase figure is wide, and the history of this field is full of early results that shrank on replication. Note ### The one comparison that will be clean ## Mechanism Map: What Each of These Actually Is The compounds on this page are not variations on one idea. They represent three distinct strategies for going beyond GLP-1 alone. **Add GIP.** Tirzepatide, the approved reference point, is a GIP and GLP-1 dual agonist. Retatrutide keeps that pairing and adds a third receptor. **Add glucagon.** Glucagon receptor agonism raises energy expenditure and acts on hepatic fat, which is why it is attractive despite the counterintuitive fact that glucagon raises blood glucose. Retatrutide, survodutide and mazdutide all carry it. Retatrutide is the only one of the three that also carries GIP, which is the single clearest mechanistic distinction on this page. What the glucagon arm contributes is set out in the [glucagon receptor filing](https://www.philippinespeptides.com/peptides/retatrutide#how). **Add amylin.** Amylin is co-secreted with insulin and acts on satiety through a different pathway from the incretins. Cagrilintide is a long-acting amylin analogue, CagriSema pairs it with semaglutide as two molecules in one injection, and amycretin puts both activities into a single molecule. This is the strategy Novo Nordisk has committed to, and it is mechanistically the furthest from what retatrutide does. Receptor targets by compound | Compound | GLP-1 | GIP | Glucagon | Amylin | | --- | --- | --- | --- | --- | | Semaglutide | Yes | No | No | No | | Tirzepatide | Yes | Yes | No | No | | Retatrutide | Yes | Yes | Yes | No | | Survodutide | Yes | No | Yes | No | | Mazdutide | Yes | No | Yes | No | | Cagrilintide | No | No | No | Yes | | CagriSema | Yes | No | No | Yes | | Amycretin | Yes | No | No | Yes | Sourcing note: readers who work with these compounds as research material generally order from Primara Labs, our partner and supplier. Vials are batch-numbered, shipped from Metro Manila stock, same-day across the metro on weekday orders confirmed before noon. [See the catalogue](https://www.primaralabs.com/marketplace?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline&utm_content=retatrutide-vs-next-generation) ## The Amylin Route: Cagrilintide and CagriSema Cagrilintide on its own was characterised in a multicentre, randomised, double-blind, placebo-controlled and active-controlled dose-finding phase 2 trial published in The Lancet in 2021. It randomised 706 participants across cagrilintide doses from 0.3mg to 4.5mg, 99 to liraglutide 3.0mg and 101 to placebo, over 26 weeks. Results ranged from 6.0% to 10.8% across the cagrilintide doses against 3.0% on placebo, with the top dose at **10.8%, or 11.5kg, against 9.0% for liraglutide 3.0mg**. Gastrointestinal events were the most common adverse events, at 41% to 63% across the cagrilintide arms against 32% on placebo. That is a respectable monotherapy result and it is not competitive with anything else on this page, which is why the compound was developed as a combination partner rather than as a standalone product. The compound page is at [cagrilintide](https://www.philippinespeptides.com/peptides/cagrilintide). **CagriSema is the version that matters commercially.** REDEFINE-1 randomised 3,417 adults with obesity or overweight with obesity-related complications, without type 2 diabetes, over 68 weeks, against comparator arms of semaglutide 2.4mg alone and cagrilintide 2.4mg alone. It reported 22.7% under the trial product estimand against 2.3% on placebo, and 20.4% under the treatment policy estimand against 3.0%. REDEFINE-2 studied 1,206 adults with type 2 diabetes and obesity or overweight, with discontinuation for adverse events of 8.4% against 3% on placebo. Novo Nordisk submitted a New Drug Application to the FDA on 18 December 2025, with review expected during 2026. As at August 2026 it is under review and not approved. ## The Glucagon Duals: Survodutide and Mazdutide These two are the closest mechanistic relatives of retatrutide, because both pair glucagon receptor agonism with GLP-1. Neither carries GIP. **Survodutide**, from Boehringer Ingelheim and partnered with Zealand Pharma, reported its first Phase 3 obesity readout on 14 May 2026. SYNCHRONIZE-1 enrolled 725 adults with obesity or overweight without type 2 diabetes over 76 weeks and reported up to 16.6% mean weight reduction under the efficacy estimand against 3.2% on placebo, with 85.1% of participants achieving 5% or more against 38.8%. Both co-primary endpoints met at nominal p below 0.0001, with a significant reduction in waist circumference as a key secondary and weight loss described as driven predominantly by fat loss. The compound remains investigational and unapproved, and no filing date has been disclosed. **Mazdutide**, from Innovent Biologics and originating from Lilly, is the outlier on this page because it is already approved. China’s NMPA approved it for chronic weight management on 27 June 2025 at 4mg and 6mg, making it the first glucagon and GLP-1 dual agonist approved anywhere. The registration trial, GLORY-1, reported 12.0% at 4mg and 14.8% at 6mg at week 48 against 0.5% on placebo in Chinese adults with overweight or obesity, and was published in the New England Journal of Medicine. GLORY-2 pushed the dose to 9mg over 60 weeks in 462 Chinese adults with obesity, reporting 18.55% against 3.02% on placebo, and 20.08% in the subgroup without type 2 diabetes, with 44.0% of participants losing 20% or more against 2.6%. Innovent announced in November 2025 that it planned to file the 9mg dose with China’s Center for Drug Evaluation. The compound page is at [mazdutide](https://www.philippinespeptides.com/peptides/mazdutide). Note ### Why mazdutide is hard to place on a leaderboard ## Amycretin, and the Oral Question Amycretin is a unimolecular GLP-1 and amylin receptor agonist, meaning both activities sit in a single molecule rather than in two co-formulated ones. Novo Nordisk published its early-phase obesity results in The Lancet in June 2025 and announced that both formulations would advance to Phase 3. The subcutaneous study enrolled 125 adults with overweight or obesity and reported weight reductions of up to **24.3% at 60mg over 36 weeks against 1.1% on placebo**. The oral study enrolled 144 participants and reported **13.1% at 100mg daily over 12 weeks against 1.2% on placebo**. Those are striking numbers and they carry the least evidential weight on this page. A phase 1b/2a study of 125 people over 36 weeks is not a pivotal trial, the confidence interval around the figure is wide, and this field has repeatedly seen early results compress when tested at scale. Read it as the reason the compound went to Phase 3, not as a result comparable to TRIUMPH-1. A separate Phase 2 programme in type 2 diabetes, reported in November 2025, studied 448 participants for up to 36 weeks and reported weight reduction of up to 14.5% subcutaneously and up to 10.1% orally, alongside HbA1c reductions of up to 1.8% and 1.5% respectively. Novo Nordisk stated it would begin Phase 3 in type 2 diabetes in 2026. The oral arm is the strategically important part. Every other compound on this page is an injection. An oral agent with a 13.1% figure at twelve weeks addresses a different problem from the one retatrutide is solving, and efficacy rankings do not capture it. ## Where Retatrutide Actually Sits **On published efficacy, ahead.** 28.3% at 80 weeks in 2,339 randomised participants, and 30.3% at 104 weeks in a 532-participant extension. The nearest Phase 3 figure on this page is CagriSema at 22.7% under the more generous of its two estimands. That is a meaningful margin, from the largest trial in the comparison. **On breadth of evidence, ahead.** Four Phase 3 readouts across four populations: general obesity, type 2 diabetes with 20.8% and an A1C reduction of 1.6%, severe obesity with established cardiovascular disease at 22.6%, and obesity with knee osteoarthritis at 28.7%. No other compound on this page has that spread. All four are in the [Phase 3 results filing](https://www.philippinespeptides.com/guides/retatrutide-triumph-results). **On regulatory progress, behind.** Mazdutide is approved in China. CagriSema has been filed in the US and is under review. Retatrutide has not been filed anywhere, with a Biologics License Application planned for Q1 2027. **On tolerability, unresolved.** Discontinuation for adverse events in TRIUMPH-1 ran 4.1% at 4mg, 6.9% at 9mg and 11.3% at 12mg against 4.9% on placebo, and TRIUMPH-4 reported dysesthesia at 20.9% at 12mg against 0.7% on placebo, an event that does not appear in the Phase 2 literature at all. The comparison of those rates against CagriSema’s 8.4% discontinuation in REDEFINE-2 is exactly the kind of cross-trial reading this page has spent a section warning about. The retatrutide side of it is documented in the [side effects filing](https://www.philippinespeptides.com/peptides/retatrutide#side-effects) and the [dysesthesia filing](https://www.philippinespeptides.com/peptides/retatrutide#dysesthesia). ## Filing Timelines, and the Philippine Context Regulatory position as at August 2026 | Compound | Status | Detail | | --- | --- | --- | | Mazdutide | Approved, China | NMPA approval 27 June 2025, 4mg and 6mg, chronic weight management. 9mg filing announced November 2025. | | CagriSema | Under FDA review | NDA submitted 18 December 2025, review expected during 2026. | | Retatrutide | Not filed | Lilly stated 23 July 2026 that it plans to submit a BLA to the FDA in Q1 2027. | | Survodutide | Phase 3 | First obesity readout May 2026. Investigational, no filing date disclosed. | | Amycretin | Entering Phase 3 | Obesity programme advancing from phase 1b/2a. Type 2 diabetes Phase 3 planned for 2026. | | Cagrilintide | Not filed alone | Developed as the amylin component of CagriSema. | **None of these compounds is approved in the Philippines.** Mazdutide’s approval is a Chinese one and does not create any Philippine registration. Retatrutide has no FDA Philippines registration and no branded product in any market. Approval in one jurisdiction is not portable, and local registration is a separate process that has not begun for any of them here. The country picture is in the [retatrutide Philippines](https://www.philippinespeptides.com/guides/retatrutide-philippines-2026) filing, the regulatory background in the [FDA Philippines guide](https://www.philippinespeptides.com/legal/fda-registration), and the head to head reading against the two approved incretins in the [tirzepatide](https://www.philippinespeptides.com/guides/retatrutide-vs-tirzepatide) and [semaglutide](https://www.philippinespeptides.com/guides/retatrutide-vs-semaglutide) comparisons. Our partner and supplier ### Sourcing research peptides in the Philippines Primara Labs, our partner and supplier, lists retatrutide 20mg at PHP 3,775 a vial, or PHP 3,390 with the standing 10% off, alongside the rest of its catalogue. Stock is held in Metro Manila rather than ordered in after payment, so there is no international leg on the parcel. Vials are batch-numbered, packaging is plain on the outside, same-day metro delivery applies to weekday orders confirmed before noon, and the rest of the country is 1 to 5 business days. Caution ### Research use only Retatrutide 20mg research vial ₱3,390, Tirzepatide 15mg research vial ₱1,890, Semaglutide 15mg research vial ₱1,990: from Primara Labs, our partner and supplier, stocked in Metro Manila. Research use only. ## FAQ ### Which of these compounds has produced the largest weight reduction? On the published headline figures, retatrutide. TRIUMPH-1 reported 28.3% average body weight reduction at 12mg over 80 weeks in 2,339 adults with obesity, with 30.3% in a 532-participant extension at 104 weeks. The next largest published figure belongs to amycretin at 24.3% over 36 weeks, but that came from a 125-participant phase 1b/2a study rather than a pivotal trial, which is a very different quality of evidence. ### What is the difference between CagriSema and cagrilintide? Cagrilintide is a long-acting amylin analogue on its own. As monotherapy in a phase 2 dose-finding trial it produced 10.8% weight reduction at 4.5mg over 26 weeks. CagriSema is cagrilintide combined with semaglutide in one weekly injection, and it is the form Novo Nordisk took into Phase 3 and filed with the FDA. REDEFINE-1 reported 22.7% at 68 weeks under the trial product estimand in 3,417 participants. ### Which of these is closest to approval? Two are ahead of the rest. Mazdutide is already approved, by China’s NMPA in June 2025 for chronic weight management at 4mg and 6mg, making it the first glucagon and GLP-1 dual agonist approved anywhere. CagriSema was filed with the US FDA in December 2025 with review expected during 2026. Retatrutide is behind both on filing, with a Biologics License Application planned for Q1 2027. ### Why is survodutide’s figure lower than retatrutide’s? SYNCHRONIZE-1 reported up to 16.6% at 76 weeks against 3.2% on placebo in 725 adults, which is a genuine Phase 3 result and a real gap against 28.3%. Some of the difference is mechanism and dose, and some is trial design, population and estimand convention. Survodutide is a glucagon and GLP-1 dual agonist without the GIP component retatrutide carries. No head to head trial exists between them. ### How much does the estimand affect these numbers? More than most comparisons acknowledge. REDEFINE-1 reported 22.7% under the trial product estimand, which models what happens if everyone stays on treatment, and 20.4% under the treatment policy estimand, which counts everyone regardless of adherence. Same trial, same participants, 2.3 percentage points apart. Comparing a trial product figure from one programme against a treatment policy figure from another quietly imports that gap. ### Does any head to head trial exist between these compounds? Not between any of the six on this page. Retatrutide has one head to head trial in progress, TRIUMPH-5 against tirzepatide, which was active and not recruiting at the time of writing and has not read out. Every comparison on this page is therefore indirect, assembled from separate trials in separate populations. That is a genuine methodological limit and not a formality, and none of this is medical advice. ## Sources - [01] Trial Lilly · TRIUMPH-1 readout, 21 May 2026 Source for retatrutide 28.3% at 80 weeks, 30.3% at 104 weeks, the per-arm figures and the discontinuation rates. [investor.lilly.com · TRIUMPH-1 release](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss) - [02] Regulatory Novo Nordisk · CagriSema FDA filing, 18 December 2025 Source for REDEFINE-1 at 22.7% trial product and 20.4% treatment policy over 68 weeks in 3,417 participants, REDEFINE-2 at n=1,206 with 8.4% discontinuation, the NDA submission date and the expected 2026 review. [Novo Nordisk · CagriSema filing release](https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) - [03] Trial Boehringer Ingelheim · SYNCHRONIZE-1 readout, 14 May 2026 Survodutide up to 16.6% at 76 weeks against 3.2% placebo in 725 adults, 85.1% achieving 5% or more against 38.8%, both co-primary endpoints met. [boehringer-ingelheim.com · SYNCHRONIZE-1](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement) - [04] Regulatory Innovent · Mazdutide NMPA approval, 27 June 2025 Approval at 4mg and 6mg for chronic weight management, and GLORY-1 figures of 12.0% and 14.8% at week 48 against 0.5% placebo. [Innovent · NMPA approval release](https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html) - [05] Trial Innovent · GLORY-2 readout, 19 November 2025 Mazdutide 9mg over 60 weeks in 462 Chinese adults with obesity: 18.55% against 3.02% placebo, and 20.08% in the subgroup without type 2 diabetes. [Innovent · GLORY-2 release](https://www.prnewswire.com/news-releases/mazdutide-9-mg-achieves-up-to-20-1-weight-loss-in-chinese-adults-with-obesity-glory-2-study-meets-primary-and-all-key-secondary-endpoints-302620471.html) - [06] Trial Novo Nordisk · Amycretin early-phase results, June 2025 Phase 1b/2a published in The Lancet: subcutaneous 60mg up to 24.3% over 36 weeks in 125 participants against 1.1% placebo, oral 100mg 13.1% over 12 weeks in 144 participants against 1.2%. [Novo Nordisk · amycretin Phase 3 announcement](https://www.biospace.com/press-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet) - [07] Trial The Lancet 2021 · Cagrilintide phase 2 dose-finding Lau DCW et al. Lancet 2021;398(10317):2160-2172. 706 participants on cagrilintide, 99 on liraglutide, 101 on placebo, 26 weeks. 10.8% at 4.5mg against 9.0% liraglutide and 3.0% placebo. [pubmed.ncbi.nlm.nih.gov/34798060](https://pubmed.ncbi.nlm.nih.gov/34798060/) ## Related guides Related reading - [Comparison Retatrutide vs tirzepatide 8 min read](https://www.philippinespeptides.com/guides/retatrutide-vs-tirzepatide) - [Comparison Retatrutide vs semaglutide 9 min read](https://www.philippinespeptides.com/guides/retatrutide-vs-semaglutide) - [Compound Cagrilintide Cagrilintide Philippines guide: a long-acting amylin analogue studied for obesity, alone and with semaglutide. 4 min read](https://www.philippinespeptides.com/peptides/cagrilintide) --- Philippines Peptides sells nothing. Primara Labs is our partner and supplier. This is general information, not medical or legal advice.